17 June 2019
The pharmaceutical cluster in the Kaluga region saw its revenue grow ten-fold since 2012 to 50 billion rubles in 2018.
The cluster employs 10,000 personnel. It encompasses effective industrial infrastructure and specialized engineering centers with a dual system of training personnel, training programs authored by pharmaceutical companies, as well as associated production facilities, the regional government’s press service reported, citing the region’s top economic development official Ilya Veselov.
The Kaluga pharmaceutical, biotechnological and biomedical cluster makes nearly 160 drugs. Thirty other drugs are being registered and 20 more are under development.
The cluster was set up in 2011. In March 2012 it was given the status of Kaluga Pharmaceutical Cluster Association with 63 members, among them international and Russian pharmaceutical concerns, small and medium innovative companies, and leading research and training centers. By 2020, its segment on the Russian pharmaceutical market is expected to increase to 10%-12%. The cluster management hopes it will become one of Russia’s top three pharmaceutical clusters in the future.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024
Microbial burden assessment of solid pharmaceutical products
22 April 2024
Seasonal variation of microbial contamination in pharmaceutical cleanrooms
22 April 2024